Approvals for drugs from Biogen Inc. and Sarepta Therapeutics Inc. show flaws in the process US drug regulators use to speed ...
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
A report from the U.S. FDA's Office of Inspector General is calling into question the thoroughness of the agency's ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
The FDA established its accelerated approval program in 1992 to allow drugs to reach the market quickly for life-threatening ...
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
2d
Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Sell rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
Mike Morin: We’re very proud to represent Sarepta Therapeutics, an innovative biotechnology company that focuses exclusively ...
Mizuho Securities analyst Uy Ear has assigned their bullish stance on SRPT stock, giving a Buy rating yesterday.Stay Ahead of the ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reported ...
An OIG report zeroed in on what it said were three particularly problematic accelerated approvals: Biogen’s Aduhelm, ...
Sarepta Therapeutics exceeded 2024 net product revenue guidance and reaffirmed its 2025 outlook, partly due to strong growth for Duchenne muscular dystrophy drug Elevidys.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback